Myalgic encephalomyelitis/chronic fatigue syndrome: A comprehensive review

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease of unknown aetiology that is recognized by the World Health Organization (WHO) and the United States Center for Disease Control and Prevention (US CDC) as a disorder of the brain. The disease predominantly...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2019
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23851
Acceso en línea:
https://doi.org/10.3390/diagnostics9030091
https://repository.urosario.edu.co/handle/10336/23851
Palabra clave:
2',5' oligoadenylate synthetase
Hydrocortisone
Immunoglobulin
Neurotransmitter
Ribonuclease l
Serotonin
Autoimmunity
B lymphocyte subpopulation
Cell activation
Central nervous system disease
Chronic fatigue syndrome
Clinical feature
Dna modification
Epigenetics
Genetic predisposition
Glia cell
Human
Hydrocortisone blood level
Hypothalamus hypophysis adrenal system
Immune dysregulation
Immune system
Immunoglobulin blood level
Inflammation
Natural killer cell
Nervous system inflammation
Neuroendocrinology
Neuroimmunology
Oxidative stress
Pathophysiology
Prognosis
Review
Sensitization
Serotoninergic transmission
Biomarker
Chronic fatigue syndrome
Epstein barr virus
Hypothalamic–pituitary–adrenal axis
Immunological
Myalgic encephalomyelitis
Neuroimmune
Rights
License
Abierto (Texto Completo)
Description
Summary:Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease of unknown aetiology that is recognized by the World Health Organization (WHO) and the United States Center for Disease Control and Prevention (US CDC) as a disorder of the brain. The disease predominantly affects adults, with a peak age of onset of between 20 and 45 years with a female to male ratio of 3:1. Although the clinical features of the disease have been well established within diagnostic criteria, the diagnosis of ME/CFS is still of exclusion, meaning that other medical conditions must be ruled out. The pathophysiological mechanisms are unclear but the neuro-immuno-endocrinological pattern of CFS patients gleaned from various studies indicates that these three pillars may be the key point to understand the complexity of the disease. At the moment, there are no specific pharmacological therapies to treat the disease, but several studies’ aims and therapeutic approaches have been described in order to benefit patients’ prognosis, symptomatology relief, and the recovery of pre-existing function. This review presents a pathophysiological approach to understanding the essential concepts of ME/CFS, with an emphasis on the population, clinical, and genetic concepts associated with ME/CFS. © 2019 by the authors.